Cargando…
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial
IMPORTANCE: Glioblastoma is the most lethal primary brain cancer. Clinical outcomes for glioblastoma remain poor, and new treatments are needed. OBJECTIVE: To investigate whether adding autologous tumor lysate-loaded dendritic cell vaccine (DCVax-L) to standard of care (SOC) extends survival among p...
Ejemplares similares
-
Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
por: Liau, Linda M., et al.
Publicado: (2018) -
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
por: Liau, Linda M., et al.
Publicado: (2018) -
Use of FLOSEAL® as a scaffold and its impact on induced neural stem cell phenotype, persistence, and efficacy
por: Bomba, Hunter N., et al.
Publicado: (2022) -
Dimorphic glioblastoma with glial and epithelioid phenotypes: Clonal evolution and immune selection
por: Mondia, Mark Willy L., et al.
Publicado: (2023) -
SUN-443 Surgical Management of Cystic Prolactinomas
por: Nevzati, Edin, et al.
Publicado: (2019)